...
首页> 外文期刊>Trials >Peritoneal flap for lymphocele prophylaxis following robotic-assisted laparoscopic radical prostatectomy with pelvic lymph node dissection: study protocol and trial update for the randomized controlled PELYCAN study
【24h】

Peritoneal flap for lymphocele prophylaxis following robotic-assisted laparoscopic radical prostatectomy with pelvic lymph node dissection: study protocol and trial update for the randomized controlled PELYCAN study

机译:腹膜皮瓣腹膜瓣腹膜腹膜腹腔镜,后腹腔淋巴结解剖术后:随机控制私人研究的研究方案和试验更新

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Data from interventional studies suggest that a peritoneal flap after pelvic lymph node dissection (LND) during laparoscopic, robotic-assisted radical prostatectomy (RARP) may reduce the rate of symptomatic lymphoceles in transperitoneal approach. However, most of these studies are not conducted in a randomized controlled fashion, thus limiting their scientific value. A recent prospective, randomized, controlled trial (RCT) did not show superiority of a peritoneal flap while further trials are lacking. Therefore, the aim of the presented RCT will be to show that creating a peritoneal flap decreases the rate of symptomatic lymphoceles compared to the current standard procedure without creation of a flap. PELYCAN is a parallel-group, patient- and assessor-blinded, phase III, adaptive randomized controlled superiority trial. Men with histologically confirmed prostate cancer who undergo transperitoneal RARP with pelvic LND will be randomly assigned in a 1:1 ratio to two groups—either with creating a peritoneal flap (PELYCAN) or without creating a peritoneal flap (control). Sample size calculation yielded a sample size of 300 with a planned interim analysis after 120 patients, which will be performed by an independent statistician. This provides a possibility for early stopping or sample size recalculation. Patients will be stratified for contributing factors for the development of postoperative lymphoceles. The primary outcome measure will be the rate of symptomatic lymphoceles in both groups within 6?months postoperatively. Patients and assessors will be blinded for the intervention until the end of the follow-up period of 6?months. The surgeon will be informed about the randomization result after performance of vesicourethral anastomosis. Secondary outcome measures include asymptomatic lymphoceles at the time of discharge and within 6?months of follow-up, postoperative complications, mortality, re-admission rate, and quality of life assessed by the EORTC QLQ-C30 questionnaire. The PELYCAN study is designed to assess whether the application of a peritoneal flap during RARP reduces the rate of symptomatic lymphoceles, as compared with the standard operation technique. In case of superiority of the intervention, this peritoneal flap may be suggested as a new standard of care. German Clinical Trials Register DRKS00016794 . Registered on 14 May 2019.
机译:介入研究的数据表明,腹腔镜腹腔镜淋巴结解剖(LND)后的腹膜皮瓣,机器人辅助的自由基前列腺切除术(RARP)可降低翻盖内方法的症状淋巴细胞率。然而,这些研究中的大部分都不是以随机控制的方式进行的,因此限制了他们的科学价值。最近的前瞻性,随机的受控试验(RCT)没有显示出腹膜皮瓣的优越性,而缺乏进一步的试验。因此,呈现的RCT的目的是表明,与目前的标准程序相比,产生腹膜皮瓣减少了症状淋巴细胞的速率,而不会产生襟翼。 Pelycan是一个平行群,患者和评估别盲,第三阶段,适应性随机控制优势试验。具有组织学证实的前列腺癌的男性将与骨盆LND进行翻子性RARP,将在1:1的比例中随机分配到两组 - 或者与产生腹膜瓣(私人)或不产生腹膜皮瓣(控制)。样品尺寸计算产生了300个样本大小,120例患者在120名患者之后进行了计划的临时分析,这将由独立的统计学家进行。这提供了早期停止或样本尺寸重新计算的可能性。将分层患者为术后淋巴细胞发育的因素进行贡献。主要结果措施将在术后6个月内为两组症状淋巴细胞率。患者和评估员将在干预方面蒙蔽,直到6个月的后续时间结束。外科医生将被告知vesicourethral吻合术后随机化结果。二次结果措施包括排放时的无症状淋巴细胞,在6?几个月内的后续,术后并发症,重新入场率和EORTC QLQ-C30问卷评估的生活质量。私有的研究旨在评估在Rarp期间腹膜皮瓣的应用是否降低了与标准操作技术相比的症状淋巴细胞的速率。在干预的优越性的情况下,这种腹膜皮瓣可能被建议为新的护理标准。德国临床试验寄存器DRKS00016794。 2019年5月14日注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号